Saturday 17 October 2026
Export MOLN’s income statement to Excel — free account
Molecular Partners AG Sponsored ADR
MOLN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 98.9%, EPS grew 34.3% and free cash flow grew 23.8%, each against the same quarter a year earlier.
3.56
0.09
−2.47%
Follow MOLN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 4 | 8 | 2 | 2 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.59 | 0.00 | 0.00 | — |
Altman Z-Score |
— | — | — | — | — | 2.61 | 7.09 | 2.11 | 2.72 | — |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 58.15 | 1.13 | 17.43 | 28.64 | — |
Altman Z″-Score (non-manufacturers) |
6.78 | — | 1.31 | (3.18) | 0.12 | (1.03) | 16.45 | 9.12 | 7.08 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.92 | 0.00 | 0.00 | — |
Beneish M-Score |
— | — | — | — | — | — | 8.60 | — | — | — |
P/Operating CF |
(17.34) | (17.34) | (17.34) | (17.34) | (17.34) | (29.21) | (15.24) | (8.02) | (11.48) | — |
P/B ratio |
5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.25 | 0.91 | 0.70 | 1.00 | — |
Price to Tangible BV |
5.49 | 5.49 | 5.49 | 5.49 | 5.49 | 5.27 | 0.91 | 0.70 | 1.01 | — |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.45 | (0.19) | (9.12) | (1.43) | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09 | 0.12 | — |
EV/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (3.02) | (0.32) | 1.09 | 0.12 | — |
EV/FCF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (3.02) | (0.33) | 1.07 | 0.12 | — |
Quick Ratio |
11.49 | 10.06 | 4.08 | 3.40 | 3.06 | 3.38 | 14.50 | 13.10 | 14.07 | 8.61 |
Current Ratio |
11.52 | 10.08 | 4.16 | 3.49 | 3.08 | 3.50 | 14.77 | 13.35 | 14.31 | 8.79 |
Net Debt/EBITDA |
9.80 | 5.71 | 2.71 | 2.71 | 3.13 | 2.18 | (2.09) | 3.18 | 2.54 | 1.66 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 2.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.14 | 0.23 | 0.06 | 0.16 | 0.06 | 0.05 | 0.86 | 0.03 | 0.03 | 0.00 |
Operating CF/Net income |
1.88 | 1.55 | 1.13 | (0.01) | 0.46 | 1.43 | 1.01 | 0.95 | 1.10 | 0.83 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | (0.58) | (0.51) | (0.59) | (0.33) | (0.31) | (0.33) |
Interest Coverage |
(116.33) | (84.73) | (107.97) | (43.15) | (12.11) | (114.06) | 188.37 | (11.85) | (1,609.64) | (11.52) |
| (14.47%) | (20.57%) | (35.54%) | (50.08%) | (78.68%) | (60.23%) | 67.89% | (31.17%) | (34.35%) | (57.72%) | |
| (11.13%) | (28.75%) | (22.31%) | (28.07%) | (43.44%) | (35.88%) | 53.26% | (27.85%) | (30.62%) | (49.07%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(11.06%) | (19.52%) | (31.41%) | (48.03%) | (48.46%) | (50.84%) | 48.16% | (33.74%) | (36.59%) | (67.69%) |
Average Days of Receivables |
13.37 | 21.03 | 1,819.36 | 36.92 | 110.82 | 959.83 | 1.96 | 101.28 | 170.16 | 0.00 |
Research and Development Expense of Revenue |
148.43% | 182.02% | 360.98% | 203.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
31.41% | 41.37% | 91.38% | 64.58% | 124.09% | 178.94% | 11.73% | 275.11% | 353.78% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 31.38% | 41.88% | 2.68% | 73.98% | 82.60% | 0.00% |
Graham Net Nets |
0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.18 | 1.07 | 1.39 | 0.97 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.40 | 0.00 | 0.00 | — |
Earnings Yield |
(11.74%) | (11.74%) | (11.74%) | (11.74%) | (11.74%) | (11.74%) | 62.97% | (50.84%) | (38.11%) | — |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (25.33%) | 52.07% | (48.75%) | (42.14%) | — |
Revenue per Share |
1.11 | 0.84 | 0.50 | 0.98 | 0.40 | 0.34 | 6.12 | 0.24 | 0.17 | 0.00 |
Operating CF per Share |
(1.68) | (1.66) | (2.01) | 0.01 | (1.24) | (3.21) | 3.83 | (2.01) | (1.98) | (1.66) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | (0.07) | (0.05) | (0.05) | (0.03) | (0.02) | (0.02) |
Free Cash Flow per Share |
(1.68) | (1.66) | (2.01) | 0.01 | (1.31) | (3.26) | 3.78 | (2.03) | (2.00) | (1.68) |
Cash per Share |
8.65 | 5.94 | 4.77 | 4.58 | 7.41 | 4.69 | 8.04 | 6.35 | 4.99 | 3.01 |
Shareholders Equity per Share |
6.52 | 4.91 | 4.42 | 2.61 | 4.57 | 3.79 | 7.59 | 6.00 | 4.73 | 2.60 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.52 | 4.91 | 4.42 | 2.61 | 4.57 | 3.79 | 7.59 | 6.00 | 4.73 | 2.60 |
Free Cash Flow |
(34.37) | (40.21) | (42.59) | 0.21 | (32.71) | (100.94) | 122.76 | (66.63) | (68.12) | (62.73) |
Working Capital |
162.54 | 131.00 | 118.83 | 73.52 | 128.14 | 128.37 | 248.88 | 198.32 | 163.00 | 103.62 |
Capital Expenditures |
(1.08) | (0.51) | (0.88) | (1.92) | (1.80) | (1.43) | (1.48) | (0.90) | (0.82) | (0.86) |
Net Current Asset Value |
130.64 | 117.17 | 91.70 | 50.64 | 103.98 | 108.11 | 238.56 | 189.96 | 156.06 | 90.65 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.05 | 0.12 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 0.13 | 0.01 | 0.11 | 0.15 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.44 | 0.61 | 0.64 | 0.58 | 0.31 | 0.31 | 0.33 | 0.43 | 0.56 | 0.41 |
Cash ROIC |
(11.09%) | (15.29%) | (21.89%) | 0.14% | (10.92%) | (38.43%) | 24.19% | (16.46%) | (20.60%) | (29.97%) |
Accounts Receivable Turnover |
22.54 | 20.38 | 0.39 | 0.77 | 3.87 | 0.69 | 13.64 | 4.83 | 2.35 | 0.00 |
Accounts Payable Turnover |
0.00 | 1.34 | 0.00 | 0.00 | 14.42 | 8.53 | 10.30 | 29.18 | 30.75 | 22.86 |
Inventory Turnover |
— | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 228.24 | 0.00 | 0.00 | 37.92 | 48.40 | 15.41 | 9.94 | 13.96 | 16.05 |
Days of Inventory on Hand |
— | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
1.00 | 1.00 | 26.92 | 27.40 | 2.58 | 15.54 | 14.57 | 1.62 | 2.40 | 2.42 |
Average Payables |
0.87 | 0.87 | 1.44 | 2.12 | 4.15 | 7.15 | 5.17 | 1.86 | 1.80 | 2.12 |
Average Assets |
163.93 | 90.24 | 169.41 | 133.25 | 154.11 | 194.48 | 231.87 | 247.88 | 200.51 | 151.66 |
Average Common Equity |
126.12 | 126.12 | 106.34 | 74.69 | 85.09 | 115.87 | 181.91 | 221.48 | 178.70 | 128.92 |
Columns are period end dates